The yin and yang of ERBB4: tumor suppressor and oncoprotein
Abstract ERBB4 (HER4) is a member of the ERBB family of receptor tyrosine kinases, a
family that includes the epidermal growth factor receptor (EGFR/ERBB1/HER1), ERBB2 …
family that includes the epidermal growth factor receptor (EGFR/ERBB1/HER1), ERBB2 …
Role of RUNX2 in Oral Squamous Cell Carcinoma (OSCC): A Systematic Scoping Review
KA AL-Hamad - European Journal of Cancer Care, 2024 - Wiley Online Library
RUNX2, known as the core‐binding factor subunit alpha‐1 (Cbfa1), is a protein‐coding
gene recognized and responsible for its involvement in bone development and osteoblast …
gene recognized and responsible for its involvement in bone development and osteoblast …
Cystatin-B Negatively Regulates the Malignant Characteristics of Oral Squamous Cell Carcinoma Possibly Via the Epithelium Proliferation/Differentiation Program
TT Xu, XW Zeng, XH Wang, LX Yang, G Luo… - Frontiers in …, 2021 - frontiersin.org
Disturbance in the proteolytic process is one of the malignant signs of tumors. Proteolysis is
highly orchestrated by cysteine cathepsin and its inhibitors. Cystatin-B (CSTB) is a general …
highly orchestrated by cysteine cathepsin and its inhibitors. Cystatin-B (CSTB) is a general …
DNA methylation in the genesis, progress and prognosis of head and neck cancer
Z Guo, W Liu, Y Yang, S Zhang, C Li… - Holistic Integrative …, 2023 - Springer
Epigenetic alteration studies in cancer research have been progressing rapidly in recent
years. DNA methylation, including DNA hypermethylation and DNA hypomethylation, is one …
years. DNA methylation, including DNA hypermethylation and DNA hypomethylation, is one …
Single-cell RNA sequencing reveals osteosarcoma microenvironment differences between chemotherapy and without chemotherapy
P Wang, H Wu, X Yao, D Ye - 2023 - researchsquare.com
Background: Osteosarcoma (OS) is considered to be the most common primary bone tumor
in adolescents. Currently, the main treatment for osteosarcoma is a combined neoadjuvant …
in adolescents. Currently, the main treatment for osteosarcoma is a combined neoadjuvant …